Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 3/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.40 |
| ▸ | CLK1 | P49759 | 3/20 | 0.40 |
| ▸ | CLK2 | P49760 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | PDE5A | O76074 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5814433 | 0.97 | CHRM4 (0.39) | CHRM4CLK4CLK1CLK2DYRK1A | |
| SCHEMBL5121202 | 0.95 | MAPT (0.44) | CHRM4CLK4CLK1CLK2DYRK1A | |
| SCHEMBL7614393 | 0.92 | ALDH1A1 (0.36) | CHRM4CLK4CLK1CLK2DYRK1A | |
| SCHEMBL5114901 | 0.91 | ALDH1A1 (0.47) | CHRM4CLK4CLK1CLK2DYRK1A | |
| SCHEMBL7515097 | 0.90 | ALDH1A1 (0.43) | CHRM4CLK4CLK1CLK2DYRK1A | |
| SCHEMBL5117152 | 0.89 | HIF1A (0.43) | CHRM4CLK4CLK1CLK2DYRK1A | |
| SCHEMBL5128036 | 0.87 | ADORA2A (0.51) | CLK4CLK1CLK2DYRK1ADYRK1B | |
| SCHEMBL5123210 | 0.86 | PDE5A (0.39) | CHRM4MAPTNPSR1ADORA2APDE5A | |
| SCHEMBL5128699 | 0.86 | MAPT (0.54) | CHRM4CLK4DYRK1AMAPTNPSR1 | |
| SCHEMBL5120075 | 0.86 | MAPT (0.45) | CLK4DYRK1AMAPTNPSR1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| EP-0920431-A1 | THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006722-A1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | CHRM4 4573/4885CLK4 2791/4885CLK1 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.